Mesothelioma patients in clinical trial see improved survival rate
Mesothelioma patients participating in a phase 3 clinical trial experienced improved survival after taking the drugs Ranirnase and Doxorubicin, according to a report presented earlier this month at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
Researchers in Germany conducted the clinical trial on patients with inoperable malignant mesothelioma, a form of cancer associated with asbestos exposure. Patients treated with the chemotherapy combination had a median survival of 11.1 months versus 10.7 months for doxorubicin plus placebo. Patients who had previously been treated with other forms of chemotherapy experienced a median survival of 10.5 months compared to 9 months for placebo. While no safety issues were noted with ranpirnase, doxorubicin is associated with side effects such as nausea and fatigue.
The report, titled “Randomized, Multicenter Phase III Study of Ranpirnase Plus Doxorubicin (DOX) in Patients with Unresectable Malignant Mesothelioma (MM),” was presented by Martin Reck, M.D., of Hospital Grosshansdorf, Hamburg, Germany.
For more information, go to: http://www.docguide.com [Doctor’s Guide].
![[Information package]](http://www.mesotheliomanews.com/wp-content/themes/biromeso/images/infopack.jpg)
